Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

Etrasimod demonstrated significant efficacy in achieving clinical remission, and was well tolerated compared to placebo in an induction and maintenance therapy.

Sandborn er al. presents the results of two phase 3 trials, ELEVATE UC 52, and ELEVATE UC 12, evaluating the safety and efficacy of etrasimod in adult patients with moderately to severely active ulcerative colitis.